The global market for Tumor Immunity Therapy is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Tumor Immunity Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Tumor Immunity Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Tumor Immunity Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Tumor Immunity Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Tumor Immunity Therapy players cover Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc and Sanofi S.A., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Tumor Immunity Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Tumor Immunity Therapy market, with both quantitative and qualitative data, to help readers understand how the Tumor Immunity Therapy market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Tumor Immunity Therapy market and forecasts the market size by Type (Immune Checkpoint Inhibitor, Cytokine Immunotherapy and Cancer Vaccine), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others
Segmentation by application
Hospital
Clinic
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure
Chapter Introduction
Chapter 1: Scope of Tumor Immunity Therapy, Research Methodology, etc.
Chapter 2: Executive Summary, global Tumor Immunity Therapy market size and CAGR, Tumor Immunity Therapy market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Tumor Immunity Therapy revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Tumor Immunity Therapy revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Tumor Immunity Therapy market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor Immunity Therapy Market Size 2017-2028
2.1.2 Tumor Immunity Therapy Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Tumor Immunity Therapy Segment by Type
2.2.1 Immune Checkpoint Inhibitor
2.2.2 Cytokine Immunotherapy
2.2.3 Cancer Vaccine
2.2.4 Car-t Cell Therapy
2.2.5 Others
2.3 Tumor Immunity Therapy Market Size by Type
2.3.1 Tumor Immunity Therapy Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Tumor Immunity Therapy Market Size Market Share by Type (2017-2022)
2.4 Tumor Immunity Therapy Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Tumor Immunity Therapy Market Size by Application
2.5.1 Tumor Immunity Therapy Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Tumor Immunity Therapy Market Size Market Share by Application (2017-2022)
3 Tumor Immunity Therapy Market Size by Player
3.1 Tumor Immunity Therapy Market Size Market Share by Players
3.1.1 Global Tumor Immunity Therapy Revenue by Players (2020-2022)
3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2020-2022)
3.2 Global Tumor Immunity Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Tumor Immunity Therapy by Regions
4.1 Tumor Immunity Therapy Market Size by Regions (2017-2022)
4.2 Americas Tumor Immunity Therapy Market Size Growth (2017-2022)
4.3 APAC Tumor Immunity Therapy Market Size Growth (2017-2022)
4.4 Europe Tumor Immunity Therapy Market Size Growth (2017-2022)
4.5 Middle East & Africa Tumor Immunity Therapy Market Size Growth (2017-2022)
5 Americas
5.1 Americas Tumor Immunity Therapy Market Size by Country (2017-2022)
5.2 Americas Tumor Immunity Therapy Market Size by Type (2017-2022)
5.3 Americas Tumor Immunity Therapy Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Immunity Therapy Market Size by Region (2017-2022)
6.2 APAC Tumor Immunity Therapy Market Size by Type (2017-2022)
6.3 APAC Tumor Immunity Therapy Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Tumor Immunity Therapy by Country (2017-2022)
7.2 Europe Tumor Immunity Therapy Market Size by Type (2017-2022)
7.3 Europe Tumor Immunity Therapy Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Immunity Therapy by Region (2017-2022)
8.2 Middle East & Africa Tumor Immunity Therapy Market Size by Type (2017-2022)
8.3 Middle East & Africa Tumor Immunity Therapy Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Tumor Immunity Therapy Market Forecast
10.1 Global Tumor Immunity Therapy Forecast by Regions (2023-2028)
10.1.1 Global Tumor Immunity Therapy Forecast by Regions (2023-2028)
10.1.2 Americas Tumor Immunity Therapy Forecast
10.1.3 APAC Tumor Immunity Therapy Forecast
10.1.4 Europe Tumor Immunity Therapy Forecast
10.1.5 Middle East & Africa Tumor Immunity Therapy Forecast
10.2 Americas Tumor Immunity Therapy Forecast by Country (2023-2028)
10.2.1 United States Tumor Immunity Therapy Market Forecast
10.2.2 Canada Tumor Immunity Therapy Market Forecast
10.2.3 Mexico Tumor Immunity Therapy Market Forecast
10.2.4 Brazil Tumor Immunity Therapy Market Forecast
10.3 APAC Tumor Immunity Therapy Forecast by Region (2023-2028)
10.3.1 China Tumor Immunity Therapy Market Forecast
10.3.2 Japan Tumor Immunity Therapy Market Forecast
10.3.3 Korea Tumor Immunity Therapy Market Forecast
10.3.4 Southeast Asia Tumor Immunity Therapy Market Forecast
10.3.5 India Tumor Immunity Therapy Market Forecast
10.3.6 Australia Tumor Immunity Therapy Market Forecast
10.4 Europe Tumor Immunity Therapy Forecast by Country (2023-2028)
10.4.1 Germany Tumor Immunity Therapy Market Forecast
10.4.2 France Tumor Immunity Therapy Market Forecast
10.4.3 UK Tumor Immunity Therapy Market Forecast
10.4.4 Italy Tumor Immunity Therapy Market Forecast
10.4.5 Russia Tumor Immunity Therapy Market Forecast
10.5 Middle East & Africa Tumor Immunity Therapy Forecast by Region (2023-2028)
10.5.1 Egypt Tumor Immunity Therapy Market Forecast
10.5.2 South Africa Tumor Immunity Therapy Market Forecast
10.5.3 Israel Tumor Immunity Therapy Market Forecast
10.5.4 Turkey Tumor Immunity Therapy Market Forecast
10.5.5 GCC Countries Tumor Immunity Therapy Market Forecast
10.6 Global Tumor Immunity Therapy Forecast by Type (2023-2028)
10.7 Global Tumor Immunity Therapy Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Tumor Immunity Therapy Product Offered
11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Information
11.2.2 Merck & Co., Inc. Tumor Immunity Therapy Product Offered
11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Merck & Co., Inc. Main Business Overview
11.2.5 Merck & Co., Inc. Latest Developments
11.3 Roche AG
11.3.1 Roche AG Company Information
11.3.2 Roche AG Tumor Immunity Therapy Product Offered
11.3.3 Roche AG Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Roche AG Main Business Overview
11.3.5 Roche AG Latest Developments
11.4 AstraZeneca, Plc
11.4.1 AstraZeneca, Plc Company Information
11.4.2 AstraZeneca, Plc Tumor Immunity Therapy Product Offered
11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 AstraZeneca, Plc Main Business Overview
11.4.5 AstraZeneca, Plc Latest Developments
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Information
11.5.2 Sanofi S.A. Tumor Immunity Therapy Product Offered
11.5.3 Sanofi S.A. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Sanofi S.A. Main Business Overview
11.5.5 Sanofi S.A. Latest Developments
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Information
11.6.2 Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offered
11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Dendreon Pharmaceuticals Main Business Overview
11.6.5 Dendreon Pharmaceuticals Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Tumor Immunity Therapy Product Offered
11.7.3 Novartis Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Information
11.8.2 Gilead Sciences Inc. Tumor Immunity Therapy Product Offered
11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 Gilead Sciences Inc. Main Business Overview
11.8.5 Gilead Sciences Inc. Latest Developments
11.9 IMVAQ Therapeutics
11.9.1 IMVAQ Therapeutics Company Information
11.9.2 IMVAQ Therapeutics Tumor Immunity Therapy Product Offered
11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 IMVAQ Therapeutics Main Business Overview
11.9.5 IMVAQ Therapeutics Latest Developments
11.10 Arch Oncology
11.10.1 Arch Oncology Company Information
11.10.2 Arch Oncology Tumor Immunity Therapy Product Offered
11.10.3 Arch Oncology Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Arch Oncology Main Business Overview
11.10.5 Arch Oncology Latest Developments
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Information
11.11.2 Juno Therapeutics Tumor Immunity Therapy Product Offered
11.11.3 Juno Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.11.4 Juno Therapeutics Main Business Overview
11.11.5 Juno Therapeutics Latest Developments
11.12 Refuge
11.12.1 Refuge Company Information
11.12.2 Refuge Tumor Immunity Therapy Product Offered
11.12.3 Refuge Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.12.4 Refuge Main Business Overview
11.12.5 Refuge Latest Developments
11.13 Lepu Biopharma
11.13.1 Lepu Biopharma Company Information
11.13.2 Lepu Biopharma Tumor Immunity Therapy Product Offered
11.13.3 Lepu Biopharma Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.13.4 Lepu Biopharma Main Business Overview
11.13.5 Lepu Biopharma Latest Developments
11.14 Genoimmune
11.14.1 Genoimmune Company Information
11.14.2 Genoimmune Tumor Immunity Therapy Product Offered
11.14.3 Genoimmune Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.14.4 Genoimmune Main Business Overview
11.14.5 Genoimmune Latest Developments
11.15 TCR Cure
11.15.1 TCR Cure Company Information
11.15.2 TCR Cure Tumor Immunity Therapy Product Offered
11.15.3 TCR Cure Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2020-2022)
11.15.4 TCR Cure Main Business Overview
11.15.5 TCR Cure Latest Developments
12 Research Findings and Conclusion
List of Tables
Table 1. Tumor Immunity Therapy Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Immune Checkpoint Inhibitor
Table 3. Major Players of Cytokine Immunotherapy
Table 4. Major Players of Cancer Vaccine
Table 5. Major Players of Car-t Cell Therapy
Table 6. Major Players of Others
Table 7. Tumor Immunity Therapy Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Tumor Immunity Therapy Market Size by Type (2017-2022) & ($ Millions)
Table 9. Global Tumor Immunity Therapy Market Size Market Share by Type (2017-2022)
Table 10. Tumor Immunity Therapy Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 11. Global Tumor Immunity Therapy Market Size by Application (2017-2022) & ($ Millions)
Table 12. Global Tumor Immunity Therapy Market Size Market Share by Application (2017-2022)
Table 13. Global Tumor Immunity Therapy Revenue by Players (2020-2022) & ($ Millions)
Table 14. Global Tumor Immunity Therapy Revenue Market Share by Player (2020-2022)
Table 15. Tumor Immunity Therapy Key Players Head office and Products Offered
Table 16. Tumor Immunity Therapy Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Tumor Immunity Therapy Market Size by Regions 2017-2022 & ($ Millions)
Table 20. Global Tumor Immunity Therapy Market Size Market Share by Regions (2017-2022)
Table 21. Americas Tumor Immunity Therapy Market Size by Country (2017-2022) & ($ Millions)
Table 22. Americas Tumor Immunity Therapy Market Size Market Share by Country (2017-2022)
Table 23. Americas Tumor Immunity Therapy Market Size by Type (2017-2022) & ($ Millions)
Table 24. Americas Tumor Immunity Therapy Market Size Market Share by Type (2017-2022)
Table 25. Americas Tumor Immunity Therapy Market Size by Application (2017-2022) & ($ Millions)
Table 26. Americas Tumor Immunity Therapy Market Size Market Share by Application (2017-2022)
Table 27. APAC Tumor Immunity Therapy Market Size by Region (2017-2022) & ($ Millions)
Table 28. APAC Tumor Immunity Therapy Market Size Market Share by Region (2017-2022)
Table 29. APAC Tumor Immunity Therapy Market Size by Type (2017-2022) & ($ Millions)
Table 30. APAC Tumor Immunity Therapy Market Size Market Share by Type (2017-2022)
Table 31. APAC Tumor Immunity Therapy Market Size by Application (2017-2022) & ($ Millions)
Table 32. APAC Tumor Immunity Therapy Market Size Market Share by Application (2017-2022)
Table 33. Europe Tumor Immunity Therapy Market Size by Country (2017-2022) & ($ Millions)
Table 34. Europe Tumor Immunity Therapy Market Size Market Share by Country (2017-2022)
Table 35. Europe Tumor Immunity Therapy Market Size by Type (2017-2022) & ($ Millions)
Table 36. Europe Tumor Immunity Therapy Market Size Market Share by Type (2017-2022)
Table 37. Europe Tumor Immunity Therapy Market Size by Application (2017-2022) & ($ Millions)
Table 38. Europe Tumor Immunity Therapy Market Size Market Share by Application (2017-2022)
Table 39. Middle East & Africa Tumor Immunity Therapy Market Size by Region (2017-2022) & ($ Millions)
Table 40. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Region (2017-2022)
Table 41. Middle East & Africa Tumor Immunity Therapy Market Size by Type (2017-2022) & ($ Millions)
Table 42. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Type (2017-2022)
Table 43. Middle East & Africa Tumor Immunity Therapy Market Size by Application (2017-2022) & ($ Millions)
Table 44. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Application (2017-2022)
Table 45. Key Market Drivers & Growth Opportunities of Tumor Immunity Therapy
Table 46. Key Market Challenges & Risks of Tumor Immunity Therapy
Table 47. Key Industry Trends of Tumor Immunity Therapy
Table 48. Global Tumor Immunity Therapy Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 49. Global Tumor Immunity Therapy Market Size Market Share Forecast by Regions (2023-2028)
Table 50. Global Tumor Immunity Therapy Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 51. Global Tumor Immunity Therapy Market Size Market Share Forecast by Type (2023-2028)
Table 52. Global Tumor Immunity Therapy Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 53. Global Tumor Immunity Therapy Market Size Market Share Forecast by Application (2023-2028)
Table 54. Bristol-Myers Squibb Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 55. Bristol-Myers Squibb Tumor Immunity Therapy Product Offered
Table 56. Bristol-Myers Squibb Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 57. Bristol-Myers Squibb Main Business
Table 58. Bristol-Myers Squibb Latest Developments
Table 59. Merck & Co., Inc. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 60. Merck & Co., Inc. Tumor Immunity Therapy Product Offered
Table 61. Merck & Co., Inc. Main Business
Table 62. Merck & Co., Inc. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 63. Merck & Co., Inc. Latest Developments
Table 64. Roche AG Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 65. Roche AG Tumor Immunity Therapy Product Offered
Table 66. Roche AG Main Business
Table 67. Roche AG Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 68. Roche AG Latest Developments
Table 69. AstraZeneca, Plc Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 70. AstraZeneca, Plc Tumor Immunity Therapy Product Offered
Table 71. AstraZeneca, Plc Main Business
Table 72. AstraZeneca, Plc Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 73. AstraZeneca, Plc Latest Developments
Table 74. Sanofi S.A. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 75. Sanofi S.A. Tumor Immunity Therapy Product Offered
Table 76. Sanofi S.A. Main Business
Table 77. Sanofi S.A. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 78. Sanofi S.A. Latest Developments
Table 79. Dendreon Pharmaceuticals Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 80. Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offered
Table 81. Dendreon Pharmaceuticals Main Business
Table 82. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 83. Dendreon Pharmaceuticals Latest Developments
Table 84. Novartis Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 85. Novartis Tumor Immunity Therapy Product Offered
Table 86. Novartis Main Business
Table 87. Novartis Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 88. Novartis Latest Developments
Table 89. Gilead Sciences Inc. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 90. Gilead Sciences Inc. Tumor Immunity Therapy Product Offered
Table 91. Gilead Sciences Inc. Main Business
Table 92. Gilead Sciences Inc. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 93. Gilead Sciences Inc. Latest Developments
Table 94. IMVAQ Therapeutics Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 95. IMVAQ Therapeutics Tumor Immunity Therapy Product Offered
Table 96. IMVAQ Therapeutics Main Business
Table 97. IMVAQ Therapeutics Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 98. IMVAQ Therapeutics Latest Developments
Table 99. Arch Oncology Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 100. Arch Oncology Tumor Immunity Therapy Product Offered
Table 101. Arch Oncology Main Business
Table 102. Arch Oncology Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 103. Arch Oncology Latest Developments
Table 104. Juno Therapeutics Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 105. Juno Therapeutics Tumor Immunity Therapy Product Offered
Table 106. Juno Therapeutics Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 107. Juno Therapeutics Main Business
Table 108. Juno Therapeutics Latest Developments
Table 109. Refuge Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 110. Refuge Tumor Immunity Therapy Product Offered
Table 111. Refuge Main Business
Table 112. Refuge Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 113. Refuge Latest Developments
Table 114. Lepu Biopharma Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 115. Lepu Biopharma Tumor Immunity Therapy Product Offered
Table 116. Lepu Biopharma Main Business
Table 117. Lepu Biopharma Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 118. Lepu Biopharma Latest Developments
Table 119. Genoimmune Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 120. Genoimmune Tumor Immunity Therapy Product Offered
Table 121. Genoimmune Main Business
Table 122. Genoimmune Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 123. Genoimmune Latest Developments
Table 124. TCR Cure Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 125. TCR Cure Tumor Immunity Therapy Product Offered
Table 126. TCR Cure Main Business
Table 127. TCR Cure Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 128. TCR Cure Latest Developments
List of Figures
List of Figures
Figure 1. Tumor Immunity Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Tumor Immunity Therapy Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Tumor Immunity Therapy Market Size Market Share by Type in 2021
Figure 7. Tumor Immunity Therapy in Hospital
Figure 8. Global Tumor Immunity Therapy Market: Hospital (2017-2022) & ($ Millions)
Figure 9. Tumor Immunity Therapy in Clinic
Figure 10. Global Tumor Immunity Therapy Market: Clinic (2017-2022) & ($ Millions)
Figure 11. Global Tumor Immunity Therapy Market Size Market Share by Application in 2021
Figure 12. Global Tumor Immunity Therapy Revenue Market Share by Player in 2021
Figure 13. Global Tumor Immunity Therapy Market Size Market Share by Regions (2017-2022)
Figure 14. Americas Tumor Immunity Therapy Market Size 2017-2022 ($ Millions)
Figure 15. APAC Tumor Immunity Therapy Market Size 2017-2022 ($ Millions)
Figure 16. Europe Tumor Immunity Therapy Market Size 2017-2022 ($ Millions)
Figure 17. Middle East & Africa Tumor Immunity Therapy Market Size 2017-2022 ($ Millions)
Figure 18. Americas Tumor Immunity Therapy Value Market Share by Country in 2021
Figure 19. Americas Tumor Immunity Therapy Consumption Market Share by Type in 2021
Figure 20. Americas Tumor Immunity Therapy Market Size Market Share by Application in 2021
Figure 21. United States Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 22. Canada Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 23. Mexico Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 24. Brazil Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 25. APAC Tumor Immunity Therapy Market Size Market Share by Region in 2021
Figure 26. APAC Tumor Immunity Therapy Market Size Market Share by Application in 2021
Figure 27. China Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 28. Japan Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 29. Korea Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 30. Southeast Asia Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 31. India Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 32. Australia Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 33. Europe Tumor Immunity Therapy Market Size Market Share by Country in 2021
Figure 34. Europe Tumor Immunity Therapy Market Size Market Share by Type in 2021
Figure 35. Europe Tumor Immunity Therapy Market Size Market Share by Application in 2021
Figure 36. Germany Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 37. France Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 38. UK Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 39. Italy Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 40. Russia Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 41. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Region in 2021
Figure 42. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Type in 2021
Figure 43. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Application in 2021
Figure 44. Egypt Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 45. South Africa Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 46. Israel Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 47. Turkey Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 48. GCC Country Tumor Immunity Therapy Market Size Growth 2017-2022 ($ Millions)
Figure 49. Americas Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 50. APAC Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 51. Europe Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 52. Middle East & Africa Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 53. United States Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 54. Canada Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 55. Mexico Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 56. Brazil Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 57. China Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 58. Japan Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 59. Korea Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 60. Southeast Asia Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 61. India Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 62. Australia Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 63. Germany Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 64. France Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 65. UK Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 66. Italy Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 67. Russia Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 68. Spain Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 69. Egypt Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 70. South Africa Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 71. Israel Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 72. Turkey Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Figure 73. GCC Countries Tumor Immunity Therapy Market Size 2023-2028 ($ Millions)
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)